Use of nonantiarrhythmic drugs for prevention of sudden cardiac death

被引:43
作者
Alberte, C [1 ]
Zipes, DP [1 ]
机构
[1] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
关键词
ventricular fibrillation; sudden death; drugs;
D O I
10.1046/j.1540-8167.14.s9.23.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonantiarrhythmic Drugs for SCD Prevention. It is of interest that the drugs having the most significant impact on total and sudden death mortality are those without direct electrophysiologic actions on myocardial excitable tissue. This observation may provide insight into mechanisms responsible for ventricular tachyarrhythmias causing cardiac arrest. One way to think about ventricular fibrillation is that it is the final common pathway of an electrically unstable heart. After all, the heart can "die" in only three major ways: electromechanical dissociation, asystole and heart block, and ventricular fibrillation, with the latter most common. It is the "upstream" events provoking the electrical instability that these drugs probably act upon (i.e., ischemia, fibrosis). Although we unquestionably need to pursue investigations into the electrophysiology of these ventricular tachyarrhythmias, more studies need to investigate the drugs affecting upstream events, because these agents appear to yield the greatest dividends, at least for the present. This article reviews these drugs and how they may be effective.
引用
收藏
页码:S87 / S95
页数:9
相关论文
共 122 条
  • [1] Fish consumption and risk of sudden cardiac death
    Albert, CM
    Hennekens, CH
    O'Donnell, CJ
    Ajani, UA
    Carey, VJ
    Willett, WC
    Ruskin, JN
    Manson, JE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (01): : 23 - 28
  • [2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [3] THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION
    AMBROSIONI, E
    BORGHI, C
    MAGNANI, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) : 80 - 85
  • [4] Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
    Anand, SS
    Yusuf, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2058 - 2067
  • [5] [Anonymous], 1988, LANCET, V2, P349
  • [6] [Anonymous], 1986, Lancet, V1, P397
  • [8] Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction - Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
    Antman, EM
    McCabe, CH
    Gurfinkel, EP
    Turpie, AGG
    Bernink, PJLM
    Salein, D
    de Luna, AB
    Fox, K
    Lablanche, JM
    Radley, D
    Premmereur, J
    Braunwald, E
    [J]. CIRCULATION, 1999, 100 (15) : 1593 - 1601
  • [9] A COMPARISON OF RESULTS OF METAANALYSES OF RANDOMIZED CONTROL TRIALS AND RECOMMENDATIONS OF CLINICAL EXPERTS - TREATMENTS FOR MYOCARDIAL-INFARCTION
    ANTMAN, EM
    LAU, J
    KUPELNICK, B
    MOSTELLER, F
    CHALMERS, TC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (02): : 240 - 248
  • [10] INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS
    APPLEBY, P
    BAIGENT, C
    COLLINS, R
    FLATHER, M
    PARISH, S
    PETO, R
    BELL, P
    HALLS, H
    MEAD, G
    DIAZ, R
    PAOLASSO, E
    PAVIOTTI, C
    ROMERO, G
    CAMPBELL, T
    OROURKE, MF
    THOMPSON, P
    LESAFFRE, E
    VANDEWERF, F
    VERSTRAETE, M
    ARMSTRONG, PW
    CAIRNS, JA
    MORAN, C
    TURPIE, AG
    YUSUF, S
    GRANDE, P
    HEIKKILA, J
    KALA, R
    BASSAND, JP
    BOISSEL, JP
    BROCHIER, M
    LEIZOROVICZ, A
    BRUGGEMANN, T
    KARSCH, KR
    KASPER, W
    LAMMERTS, D
    NEUHAUS, KL
    MEYER, J
    SCHRODER, R
    VONESSEN, R
    SARAN, RK
    ARDISSINO, D
    BONADUCE, D
    BRUNELLI, C
    CERNIGLIARO, C
    FORESTI, A
    FRANZOSI, MG
    GUIDUCCI, D
    MAGGIONI, A
    MAGNANI, B
    MATTIOLI, G
    [J]. LANCET, 1994, 343 (8893) : 311 - 322